



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

704.CELLULAR IMMUNOTHERAPIES: EARLY PHASE AND INVESTIGATIONAL THERAPIES

Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)

Claire Roddie, MD PhD¹, Eleni Tholouli, MD PhD², Paul Shaughnessy, MD³, Elias Jabbour, MD⁴, Aaron C. Logan, MD PhD⁵, Katharine Hodby, PhD⁶, Luke Mountjoy, DO⁷, Adrian John Clifton Bloor, PhD FRCP, FRCP⁸, David Irvine, FRCP, PhD⁹, David C. Linch, MD¹⁰, Kim H. Orchard, MBBS, PhD FRCP, FRCP¹¹, William Wilson¹², Bilyana Popova, MSc¹³, Juliana Dias, PhD¹⁴, Giulia Agliardi, PhD¹⁵, Victoria Spanswick, PhD¹⁶, Helen Lowe, PhD¹⁷, Marina Mitsikakou, MRes¹⁸, Eftychia Charalambous, MSc¹⁹, Joanna Dawes, PhD²⁰, Meera Raymond, PhD²⁰, Yanqing Hu, PhD²⁰, Wolfram Brugger, MD PhD²¹, Martin A. Pule, MD²⁰, Jae H. Park, MD²², Karl Peggs, MD²³

¹ Research Department of Haematology, University College London Cancer Institute, London, United Kingdom

² Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom

³ Methodist Hospital, San Antonio, TX

⁴ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

⁵ Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, University of California at San Francisco, San Francisco, CA

⁶ University Hospital Bristol, Bristol, United Kingdom

⁷ Colorado Blood Cancer Institute, Denver, CO

⁸ Haematology and Transplant Unit, Christie NHS Foundation Trust, Manchester, United Kingdom

⁹ Stem cell transplant and Cell Therapy unit, Queen Elizabeth University Hospital, Glasgow, United Kingdom

¹⁰ Department of Haematology, Royal Free and University College London Medical School, London, United Kingdom

¹¹ University Hospital Southampton, Southampton, United Kingdom

¹² Cancer Research UK & UCL Cancer Trials Centre, University College London Cancer Institute, London, United Kingdom

¹³ Cancer Research UK & UCL Cancer Trials Centre, London, United Kingdom

¹⁴ University College London and Centre for Cell Gene and Tissue Therapeutics, Royal Free Hospital NHS Foundation, Research Department of Haematology, London, United Kingdom

¹⁵ Royal Free Hospital, Research Department of Haematology, UCL Cancer Institute, London, United Kingdom

¹⁶ UCL ECMC GCLP Facility, University College London Cancer Institute, London, United Kingdom

¹⁷ UCL ECMC GCLP Facility, UCL Cancer Institute, London, United Kingdom

¹⁸ Haematology Department, UCL Cancer Institute, London, United Kingdom

¹⁹ Research Department of Haematology, UCL Cancer Institute, London, United Kingdom

²⁰ Autolus Therapeutics, London, United Kingdom

²¹ Autolus Therapeutics, Munich, Germany

²² Memorial Sloan Kettering Cancer Center, New York, NY

²³ Haematology Department, UCLH, London, United Kingdom

Background: Obe-cel is an autologous CD19 chimeric antigen receptor (CAR) T cell product designed to reduce toxicity and improve persistence through a fast off-rate CD19 binding domain. The clinical activity of obe-cel has been explored in adults with R/R B-ALL in a Phase I study (ALLCAR19, NCT02935257; Roddie C et al. J Clin Oncol 2021) and a Phase Ib/II study (FELIX, NCT04404660; Roddie C et al. J Clin Oncol 2023;41[16 Suppl]:7000). Additionally, obe-cel has been tested in pts with R/R B-cell chronic lymphocytic leukemia (B-CLL) and R/R B-cell non-Hodgkin lymphoma (B-NHL) (ALLCAR19 extension; Roddie C et al. Blood 2022;140[1 Suppl]:7452-3). Pts from the ALLCAR19 and FELIX Phase Ib studies are in long-term follow up (≥ 22 mos), and the ALLCAR19 extension has been recruiting for 3 years. We report an analysis of long-term efficacy and safety data from the ALLCAR19 and FELIX Phase Ib studies, as well as data from the ALLCAR19 extension.

Methods: ALLCAR19 is a multicenter, non-randomized, open-label Phase I study in pts aged ≥ 16 years with B-cell malignancies. ALLCAR19 initially recruited pts with R/R B-ALL but was then amended (extension study) to also include pts with

R/R B-CLL and R/R B-NHL. FELIX is a global, single-arm Phase Ib/II study enrolling pts aged ≥ 18 years with R/R B-ALL. Study designs have been presented previously. Obe-cel was administered as a split dose in pts with B-ALL (target dose 410×10^6 CAR T cells) and pts with CLL (target dose 230×10^6 CAR T cells), and as a single infusion in pts with B-NHL (target dose 200×10^6 CAR T cells); the pt populations in the two studies were similar. Pts with B-ALL from the ALLCAR19 and FELIX Phase Ib studies are being followed long term for disease progression and survival. For this analysis, data in pts with B-ALL from the ALLCAR19 and FELIX Phase Ib studies were pooled. Data in pts with CLL or B-NHL are presented from the ALLCAR19 extension study.

Results: *Outcomes in pts with R/R B-ALL:* Data in pts with B-ALL were pooled (20 pts from ALLCAR19 [data cut-off Jun 26, 2023] and 16 from FELIX Phase Ib [data cut-off Mar 16, 2023]). The median age of the pooled cohort was 41.5 (range 18 to 74) years and pts had received a median of 3 (range 2 to 6) prior lines of treatment. Twenty-nine of the 36 pts (81%) achieved complete remission (CR)/CR with incomplete hematologic recovery post obe-cel infusions, per investigator assessment. The event-free survival rate was 64% at 6 mos and 49% at 12 mos. With a median follow up of 43 (range 19 to 62) mos, 13/36 pts (36%) remain in remission (8 from ALLCAR19; 5 from FELIX Phase Ib). Among these 13 ongoing responders, 2 (15%) had consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ten of the 11 ongoing responders (91%) who did not receive allo-HSCT still had detectable CAR T cells at the last follow up. All ongoing remissions were measurable residual disease negative at last available assessment. The estimated 2-, 3- and 4-year overall survival rates were 44%, 39% and 39%, respectively.

Outcomes in pts with R/R B-CLL/B-NHL: The extension phase of the ALLCAR19 study enrolled 35 pts with B-CLL or B-NHL, of which 26 (B-CLL n=5; B-NHL n=21) received obe-cel (data cut-off Jun 26, 2023). The median age of this combined cohort was 61 (range 39 to 79) years and pts had received a median of 3 (range 2 to 8) prior lines of treatment. At a median follow up of 24 mos, the overall response rate for this cohort was 92% (n=24), and 58% of responders (n=14) were alive without disease progression at last follow up.

Late toxicity: Of the 11 long-term R/R B-ALL responders who had not received consolidation allo-HSCT, 10 have ongoing B-cell aplasia. Of the 14 ongoing responders in the R/R B-CLL/B-NHL cohort, 12 have ongoing B-cell aplasia (<20 B cells/ μ l). Of note, ongoing B-cell aplasia did not correlate with an increased risk of late serious infection. No other long-term toxicity ascribed to obe-cel was reported.

Conclusions: The combined analysis of data from the ALLCAR19 and FELIX Phase Ib studies shows long-term efficacy and safety of obe-cel in pts with R/R B-ALL, with approximately one-third of pts still in remission without consolidative allo-HSCT after a median follow up of >3 years. Durable responses of >2 years were also seen in pts with R/R B-CLL and R/R B-NHL. B-cell aplasia was commonly found in long-term follow up of obe-cel recipients, but without a corresponding rise in serious late infections. Obe-cel can effect durable long-term remissions in B-cell malignancies.

Disclosures **Roddie:** Autolus Therapeutics: Research Funding; **BMS, Novartis, Kite/Gilead, Autolus Therapeutics, Amgen:** Honoraria. **Tholouli:** Autolus Therapeutics, Vertex, Jazz, Novartis: Honoraria; Vertex, Jazz, Pfizer, Kite/Gilead: Speakers Bureau. **Shaughnessy:** Autolus Therapeutics, BMS: Honoraria; BMS, Sanofi: Speakers Bureau. **Jabbour:** Takeda: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Ascentage Pharma Group: Consultancy, Honoraria, Research Funding; Adaptive Biotech: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Hikma Pharmaceuticals: Consultancy, Honoraria, Research Funding. **Logan:** Amgen, Autolus Therapeutics, Kadmon, Kite, Pharmacocyclics, Talaris: Research Funding; AbbVie, Amgen, Actinium, BMS, Pfizer, Sanofi, Takeda: Consultancy. **Hodby:** Astellas: Honoraria. **Mountjoy:** Colorado Blood Cancer Institute: Current Employment. **Bloor:** Gilead, Janssen: Honoraria; Abbvie: Consultancy, Honoraria, Speakers Bureau. **Irvine:** KITE, JANSSEN, VERTEX: Honoraria. **Linch:** Autolus Therapeutics: Consultancy. **Orchard:** GSK: Current equity holder in publicly-traded company; Takeda: Honoraria; Targeted radiotherapy: Patents & Royalties. **Popova:** Autolus Therapeutics: Research Funding; University College London: Current Employment. **Agliardi:** Cancer Research UK: Research Funding. **Lowe:** UCL (Cancer Clinical Trials): Current Employment. **Charalambous:** UCL Cancer Institute: Current Employment. **Dawes:** Autolus Therapeutics: Current Employment. **Raymond:** Autolus Therapeutics: Current Employment, Current equity holder in publicly-traded company. **Hu:** Autolus Therapeutics: Current Employment, Current equity holder in publicly-traded company; Kite Pharma: Ended employment in the past 24 months. **Brugger:** Autolus Therapeutics: Current Employment, Current equity holder in publicly-traded company. **Pule:** Autolus Therapeutics: Current Employment, Current equity holder in publicly-traded company, Other: Entitled to royalty payments from related intellectual property. **Park:** Curocell: Consultancy; Allogene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy; Servier: Consultancy, Research Funding; Be Biopharma: Consultancy; Minerva Bio: Consultancy; Incyte: Research Funding; GC Cell: Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy; Autolus Therapeutics: Research Funding; Intella: Consultancy; Takeda: Consultancy, Research Funding; Kite: Consultancy; Sobi: Consultancy, Research Funding; Bright Pharmaceuticals: Consultancy; Fate Therapeutics: Research Funding; Amgen: Consultancy; Genentech, Inc.: Research Funding; Artiva Biotherapeutics: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Affymimmune: Consultancy. **Peggs:** Autolus Therapeutics: Consultancy, Current equity holder in publicly-traded company.

<https://doi.org/10.1182/blood-2023-180666>